Yumei Yang

First report demonstrating the safety and immunogenicity of the SARS-COV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, observer-blind Phase I study

A. Hui, Ö. Türeci, U. Şahin, 2021 .

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19

Rui-Ru Ji, U. Şahin, C. Qin, 2021, Vaccines.

Cancer drug development in China: recent advances and future challenges.

Yi-long Wu, Yumei Yang, Helena Zhang, 2015, Drug discovery today.

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study

A. Hui, Ö. Türeci, U. Şahin, 2021, Nature Medicine.

Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial

W. Wang, Lei-ke Zhang, Xiangrui Jiang, 2023, The Lancet regional health. Western Pacific.

Cancer drug development in China: recent advances and future challenges.

Yi-long Wu, Yumei Yang, Helena Zhang, 2015, Drug discovery today.